Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
Consumers could pay an average 15 to 20 cents more per gallon for unleaded gas by the end of the month following the attack on Saudi oil installations.Market Insiderread more
Elliott Management may not see John Stankey as a future leader at AT&T, but bailing on him before he executes his integration plan has the potential for disaster.Technologyread more
The White House directed Lewandowski not to discuss any of his post-election interactions with Trump beyond those already detailed in former special counsel Robert Mueller's...Politicsread more
Tension between the real estate start-up WeWork and SoftBank was not a central issue in the decision to delay an initial public offering, sources tell CNBC's David FaberThe Faber Reportread more
The service will debut in April with pricing to be announced closer to the launch data, NBCUniversal says.Technologyread more
A sharp drop in mortgage rates in August was clearly behind the confidence in September. The survey came with warning signs, however. Mortgage rates shot back up at the start...Real Estateread more
U.S. manufacturing output increased more than expected in August, boosted by a surge in machinery and primary metals production.Economyread more
Pfizer has agreed to pay a little more than $80 per share for Medivation, one of the people said, a substantial premium to the $52.50 offer for Medivation that France's Sanofi made in April, which eventually resulted in the company putting itself up for sale. Medivation shares ended trading in New York on Friday at $67.16.
The strong acquisition interest in the San Francisco-based company illustrates how demand for new cancer treatments, which can possibly add years to patients' lives, could spell billions of dollars in revenue to the companies that own them.
Pfizer has so far prevailed in the auction for Medivation and could announce a deal as early as Monday, although the negotiations still could fall apart at the last minute, the people said. The deal is expected to be paid for by Pfizer in its entirety, or at least mostly, with cash, one of the people said.
The sources asked not to be identified because the negotiations are confidential. Pfizer and Medivation declined to comment. The Financial Times first reported on Pfizer nearing a deal for Medivation on Sunday.
Pfizer, whose oncology offerings include breast cancer drug Ibrance and several other promising immuno-oncology products, is now set to get access to Medivation's successful prostate cancer drug Xtandi, as well as Talazoparib, another breast cancer treatment under development by Medivation.
Medivation earlier this year rejected two acquisition offers from Sanofi, the latest for $58 per share in cash and $3 per share in the form of a contingent value right relating to the sales performance of Talazoparib.
However, Medivation agreed in July to share confidential information with potential buyers after Sanofi agreed to drop a campaign to oust Medivation's board of directors.
In its second-quarter earnings call earlier this month, Medivation reported continued double-digit year-over-year growth for Xtandi, affirming the company's expectations of more than 50 percent revenue growth for the year.
Medivation also cited positive late-stage data for Talazoparib, a drug the company believes will account for a significant part of its long-term value.